Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2025-08-12 16:00:00| Marketing Profs - Concepts, Strategies, Articles and Commentaries

Even the best B2B products can stall without clear messaging. Learn how to clarify your value proposition and accelerate sales momentum. Read more. Read the full article at MarketingProfs


Category: Marketing and Advertising

 

LATEST NEWS

2025-08-12 07:15:00| TRENDWATCHING.COM

Noom's new weight-loss program formalizes what many have been experimenting with and hyping on Reddit and TikTok: microdosing GLP-1 drugs. The digital healthcare company has launched a Microdose GLP-1Rx Program priced at USD 119 to start, followed by USD 199 monthly, which includes both medication and a "GLP-1 Companion" behavior change platform. Noom's protocol uses doses that are 25% or less of standard maintenance doses, with 70% of members reporting no side effects while still achieving significant weight loss.The approach tackles three barriers to addressing obesity through Ozempic and its brethren: medication cost, side effects and sustainable behavior change. By personalizing dosing schedules to each member rather than following a one-size-fits-all approach, Noom aims to maximize outcomes while minimizing the digestive issues that lead many to abandon GLP-1 treatments. This strategy bridges the gap between DIY experimentation and conventional medical protocols, potentially making these medications accessible to those deterred by both high costs and unpleasant side effects.TREND BITEWhile early adopters chased dramatic transformations through high-dose protocols, mainstream consumers now gravitate toward gentler interventions. Microdosing is a sign of the "Ozempic era" maturing, with preferences shifting from dramatic transformations to sustainable lifestyle integration; think less "Biggest Loser" and more "Couch to 5K." With Noom repackaging GLP-1 medication as an accessible health tool for the masses, the drugs' impact on the food industry is likely to increase. (See "Ozempic Is Costing Grocery Stores Billions" and "Ozempic Is Shrinking Appetites. Restaurants Are Shrinking the Food.")


Category: Marketing and Advertising

 

2025-08-08 16:00:00| Marketing Profs - Concepts, Strategies, Articles and Commentaries

Catch up on select AI news and developments from the past week or so. Stay in the know. Read the full article at MarketingProfs


Category: Marketing and Advertising

 

Latest from this category

15.08AI Update, August 15, 2025: AI News and Views From the Past Week
15.08Campaign turns in-game deaths into real-life organ donor registrations
14.08The Most Recommended Brands Globally and In the US [Infographic]
14.08Brand GRAVITY's Pull: Attracting B2B Byers Across Research Channels
13.08How Senior B2B Marketers Stay Sharp and Contribute as Their Roles Evolve
13.08How to Use Web Accessibility Standards to Optimize Your Conversion Rate
13.08Digital Dr Karl takes on climate skeptics with AI-powered persuasion
12.08The State of B2B Outbound Sales Outreach in 2025
Marketing and Advertising »

All news

15.08Weekly Scoreboard*
15.08Target and Ulta mutually agree not to renew partnership launched in 2021
15.08Ukraine's fate hangs in balance as Trump engages Putin in a high-stakes game behind closed doors
15.08What Makes This Trade Great: FOSLs Wild Ride
15.08Beijing files WTO suit against Canada, opposes EU sanctions on Iran
15.08US retail sales in July rise 0.5% on auto power
15.08Stocks Slightly Lower into Afternoon on Rising Long-Term Rates, Earnings Outlook Jitters, Profit-Taking, Financial/Utility Sector Weakness
15.08Washington DC sues Trump, calling police takeover illegal
More »
Privacy policy . Copyright . Contact form .